Cardiovascular Drugs

Cardiovascular Drugs Market by Drug Type (Angiotensin Inhibitors, Anticoagulants, Antihyperlipidemic), Disease Indication (Arrhythmia, Coronary Artery Disease, Hyperlipidaemia), Route of Administration, Mode of Purchase, End-Users - Global Forecast 2024-2030

360iResearch Analyst
SPEAK TO ANALYST? OR FACE-TO-FACE MEETING?
Want to know more about the cardiovascular drugs market or any specific requirement? Ketan helps you find what you're looking for.
DOWNLOAD A FREE PDF
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[192 Pages Report] The Cardiovascular Drugs Market size was estimated at USD 82.65 billion in 2023 and expected to reach USD 90.13 billion in 2024, at a CAGR 9.15% to reach USD 152.61 billion by 2030.

Cardiovascular Drugs Market
To learn more about this report, request a free PDF copy

Cardiovascular drugs encompass the range of medications prescribed for the treatment of heart diseases and related circulatory problems. This includes a variety of therapeutic drug classes, such as antihypertensives, anticoagulants, antiarrhythmics, antianginals, and cholesterol-lowering drugs. These medications are primarily used in the clinical management of conditions such as hypertension, hyperlipidemia, coronary artery disease, arrhythmias, and heart failure. The increasing incidence of cardiovascular conditions globally, especially among the aging population, is expanding the need for cardiovascular drugs. Rising healthcare spending and improvements in healthcare infrastructure in emerging economies are propelling market expansion. Adverse drug reactions and safety concerns lead to product recalls and tarnish the brand image, subsequently impacting the market growth. New advances in personalized medicine and biologics are presenting significant opportunities in the cardiovascular drug market. Additionally, rising research & development activities to introduce novel cardiovascular are expected to fuel the market growth.

Regional Insights

The Americas maintain a significant position in the global cardiovascular drugs market because of high healthcare expenditure, sophisticated healthcare infrastructure, and significant research and development activities. The U.S. market exhibits strong demand for innovative and branded drugs bolstered by a consumer base that prioritizes efficacy and brand reputation. The European Union (EU) countries exhibit a strong demand for cardiovascular drugs with a large aging population. Market dynamics in the EU are shaped by rigorous regulations and the presence of numerous global pharmaceutical players. There is a mix of preference for brand-name drugs and generics driven by cost-containment measures within various healthcare systems. In the Middle East and Africa, the market for cardiovascular drugs is evolving with rising incidence rates of heart diseases. The Asia Pacific region is rapidly emerging as a significant market for cardiovascular drugs, driven by a growing aging population and an increasing prevalence of cardiovascular diseases (CVDs). In this region, China and India are significant countries due to their large populations and the burgeoning incidence of CVDs. In terms of consumer needs, access to affordable healthcare and generic medicine is paramount due to diverse economic strata across the region.

Market Dynamics

The market dynamics represent an ever-changing landscape of the Cardiovascular Drugs Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

  • Market Drivers
    • Rising Prevalence of Cardiovascular Disorders
    • Increasing R&D Investments for Drug Development
    • Government Initiatives for Prevention & Control of Cardiovascular Diseases
  • Market Restraints
    • Product Recalls and High Cost of Cardiovascular Drugs
  • Market Opportunities
    • Favorable Reimbursement Policies and Programs for Cardiovascular Drugs
    • Introduction of Novel Drugs for Treatment of Cardiovascular Diseases
  • Market Challenges
    • Complexities in Efficient and Safe Drug Development
Market Segmentation Analysis
  • Drug Type: Increasing need for angiotensin inhibitors to treat certain types of kidney diseases

    Angiotensin inhibitors are a class of drugs used to treat conditions such as high blood pressure, heart failure, and certain types of kidney disease. These medications work by blocking the effects of angiotensin, a chemical that narrows blood vessels. The two main types of angiotensin inhibitors are Angiotensin-Converting Enzyme (ACE) inhibitors and Angiotensin II Receptor Blockers (ARBs). Anticoagulants are often referred to as blood thinners. They prevent the formation of new blood clots and stop existing clots from getting larger. This drug type is pivotal for patients with atrial fibrillation, deep vein thrombosis, pulmonary embolism, or those who have undergone certain types of surgeries. Antihyperlipidemic drugs are used to lower lipid levels in the blood, especially cholesterol. They are critical for the prevention and management of atherosclerosis and coronary artery disease. Statins are the most common class within this category. Antihypertensive drugs are used to manage hypertension (high blood pressure). This broad drug category includes a variety of medication classes, such as beta-blockers, diuretics, calcium channel blockers, etc., each with different mechanisms of action. Antiplatelet drugs inhibit platelet aggregation to prevent arterial thrombus formation. They are especially important for patients with a history of myocardial infarction, unstable angina, and those who have had stents placed or undergone coronary artery bypass graft surgery.

  • Disease Indication: Rising usage of cardiovascular diseases for the management of hypertension

    Arrhythmias are irregular heartbeats that can lead to various complications, including stroke and heart failure. Drugs used to treat arrhythmia include antiarrhythmic agents, beta-blockers, and calcium channel blockers. Commonly prescribed medications in this segment, such as amiodarone, sotalol, and digoxin, are aligned with the need to control and maintain normal heart rhythm. Coronary artery disease (CAD), a condition marked by the buildup of plaque in the coronary arteries, is commonly managed with a combination of cholesterol-lowering drugs, nitrates, beta-blockers, and antiplatelet agents. Statins are the foundation of pharmacotherapy for CAD, aimed at reducing the risk of subsequent heart attacks and other cardiovascular events. Hyperlipidaemia, characterized by elevated levels of lipids in the blood, is a key risk factor for cardiovascular disease. The therapeutic approach includes statins, fibric acid derivatives, bile acid sequestrants, and cholesterol absorption inhibitors. The goal of treatment is to lower LDL cholesterol and thereby reduce cardiovascular risk. Hypertension, or high blood pressure, is treated with several classes of drugs, including diuretics, ACE inhibitors, angiotensin II receptor blockers (ARBs), beta-blockers, and calcium channel blockers. These medications help manage blood pressure and reduce the risk of heart attack, stroke, and kidney disease.

  • Mode of Purchase: Rising usage of over-the-counter cardiovascular drugs for managing minor symptoms associated with heart health

    Over-the-counter cardiovascular drugs are medications that can be purchased without a prescription. They are generally considered safe and effective when used as directed for minor health concerns related to cardiovascular health. Consumers tend to prefer OTC drugs for managing minor symptoms associated with heart health, such as using aspirin for its blood-thinning properties to prevent heart attacks or controlling mild hypertension with garlic pills. The convenience, accessibility, and affordability of OTC drugs make them a popular choice for self-medication and proactive health care management. Prescription-based cardiovascular drugs are designed to treat more severe conditions and require a healthcare provider's authorization for use. These medications often have a more significant potential for side effects and necessitate medical oversight. The need for prescription-based drugs arises when patients experience serious cardiovascular illnesses that cannot be managed with OTC medication.

  • End-Users: Growing adoption of cardiovascular drugs by hospitals pharmacies for the treatment of acute conditions

    Hospital pharmacies represent a critical channel for the dispensation of cardiovascular drugs tailored to inpatient and outpatient needs. These facilities primarily deal with direct patient administration, including patients undergoing surgery or treatment for acute conditions. The need-based preference here is for a comprehensive range of cardiovascular medications readily available on a 24/7 basis to cater to emergency situations and ongoing patient regimens. The rise of online pharmacies has revolutionized how patients obtain their medications, cardiovascular drugs included. The primary need-based preference here is convenience, accessibility, and often competitive pricing. Patients with chronic conditions requiring ongoing medication, such as hypertension or heart failure, may find subscription services particularly appealing. Retail pharmacies serve as a vital access point for cardiovascular drugs to the general public, especially for those with less acute forms of heart disease. The preference here stems from the immediate availability of medication, personal interaction with pharmacists for consultation, and the provision of associated health monitoring services.

Market Disruption Analysis

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Cardiovascular Drugs Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Cardiovascular Drugs Market.

Porter’s Five Forces Analysis

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Cardiovascular Drugs Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

Value Chain & Critical Path Analysis

The value chain of the Cardiovascular Drugs Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

Pricing Analysis

The pricing analysis comprehensively evaluates how a product or service is priced within the Cardiovascular Drugs Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Cardiovascular Drugs Market.

Technology Analysis

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Cardiovascular Drugs Market.

Patent Analysis

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Cardiovascular Drugs Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

Trade Analysis

The trade analysis of the Cardiovascular Drugs Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

Regulatory Framework Analysis

The regulatory framework analysis for the Cardiovascular Drugs Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cardiovascular Drugs Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cardiovascular Drugs Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • Bristol Myers pours USD 100 million into RNA drugs for cardiovascular diseases

    Bristol Myers Squibb has invested over USD 100 million to enhance its collaboration with Avidity Biosciences. This strategic move underscores Bristol Myers' confidence in Avidity's innovative RNA-based therapy platform. This bold expansion marks a significant milestone in Bristol Myers Squibb’s quest to revolutionize the future landscape of cardiovascular medicine. [Published On: 2023-05-28]

  • U.S. FDA Approves Lexicon Pharma's Drug for Heart Failure

    In a significant development for Lexicon Pharmaceuticals Inc., the U.S. Food and Drug Administration (FDA) has officially approved the company's novel oral medication, sotagliflozin, to be marketed as Inpefa for the expansive treatment of heart failure, including for those patients living with type 2 diabetes. This approval marks a milestone for Lexicon, as sotagliflozin represents the first drug by Lexicon to receive endorsement from the FDA, an achievement accentuated by the drug's prior unsuccessful attempt to secure approval as a supplementary treatment to insulin for type 1 diabetes. [Published On: 2023-05-27]

  • Glenmark Pharmaceuticals Launches Drug to Treat Heart Failure in India

    Glenmark Pharmaceuticals has announced the Indian market launch of its novel combination therapy, 'Sacu V', a tablet containing sacubitril and valsartan, expressly indicated for heart failure treatment. Upholding a cost-effective strategy, 'Sacu V' is offered at a competitive price, with the 50mg dosage variant (comprising 24mg of sacubitril and 26mg of valsartan) available at INR 19 per tablet. [Published On: 2023-01-17]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cardiovascular Drugs Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Cardiovascular Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Apotex Inc., AstraZeneca PLC, Auro Pharma Inc., Bausch Health Companies Inc., Baxter International Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Chiesi USA, Inc., Cipla Limited, Cornerstone Therapeutics Inc., CYTOKINETICS, Incorporated, Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Ferring B.V., Gilead Sciences, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Holdings Co., Ltd., Par Pharmaceutical by Endo International, Pfizer Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., WellSpring Pharmaceutical Corporation, and Zydus Group.

Cardiovascular Drugs Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Market Segmentation & Coverage

This research report categorizes the Cardiovascular Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Type
    • Angiotensin Inhibitors
    • Anticoagulants
    • Antihyperlipidemic
    • Antihypertensive
    • Antiplatelet Drugs
  • Disease Indication
    • Arrhythmia
    • Coronary Artery Disease
    • Hyperlipidaemia
    • Hypertension
  • Route of Administration
    • Intravenous
    • Oral
    • Subcutaneous
  • Mode of Purchase
    • Over-The-Counter Drugs
    • Prescription-Based Drugs
  • End-Users
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

This research report offers invaluable insights into various crucial aspects of the Cardiovascular Drugs Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Cardiovascular Drugs Market, by Drug Type
  7. Cardiovascular Drugs Market, by Disease Indication
  8. Cardiovascular Drugs Market, by Route of Administration
  9. Cardiovascular Drugs Market, by Mode of Purchase
  10. Cardiovascular Drugs Market, by End-Users
  11. Americas Cardiovascular Drugs Market
  12. Asia-Pacific Cardiovascular Drugs Market
  13. Europe, Middle East & Africa Cardiovascular Drugs Market
  14. Competitive Landscape
  15. Competitive Portfolio
  16. List of Figures [Total: 26]
  17. List of Tables [Total: 470]
  18. List of Companies Mentioned [Total: 30]
Novel cardiovascular drugs: a power tool of the healthcare system
February 28, 2023
INSIGHT
Novel cardiovascular drugs: a power tool of the healthcare system
The pharmaceutical industry has gone through a major rollercoaster ride in the past few years due to the COVID-19 pandemic, geopolitics, inflation, novel therapeutic modalities, and innovative ways of working.

The pharmaceutical industry's many unique traits, both in terms of its corporate structure and the nature of its commercial operations, significantly impact the process of getting new drugs to patients.

With the growing burden of cardiovascular disease worldwide, governments of different regions and big pharmaceutical giants are inclined toward developing novel and innovative cardiovascular drugs.

In October 2021, Merck entered into a USD 11.5 billion pharma acquisition deal with biotechnology company Acceleron Pharma Inc. to strengthen its cardiovascular pipeline.

A surge of innovations is currently sweeping through the pharmaceutical industry, including new treatment modalities, intelligent machinery, cutting-edge analytics, and digital connection.

Heart failure can be managed by various self-disciplinary activities, and it has also been studied using a variety of novel treatment approaches, such as cell transplantation, gene transfer or therapy, cytokines, or other small compounds. Pharmaceutical companies also concentrate on developing nano-carriers and addressing issues with traditional and contemporary treatments, such as nonspecific effects and low stability.

Along with technological advances in medical research, cardiovascular diseases could be avoided by educating the general public about risk factors such as diabetes, high cholesterol, obesity, high blood pressure, an unhealthy diet, and tobacco use.

The Importance of Cardiovascular Drugs: An Analysis of Favorable Reimbursement Policies and Programs
October 23, 2023
BLOG
The Importance of Cardiovascular Drugs: An Analysis of Favorable Reimbursement Policies and Programs
Cardiovascular disorders are one of the primary reasons for mortality globally. In response, pharmaceutical companies have developed cardiovascular drugs to assist in the treatment and mitigation of the disease. However, the expenses incurred in developing these drugs are substantial, and without a favorable reimbursement policy, their availability to the public may be limited. This blog post discusses the importance of cardiovascular drugs, favorable reimbursement policies and programs, and how they benefit patients.

Favorable reimbursement policies and programs for cardiovascular drugs instill confidence in both patients and pharmaceutical companies. A consistent and coherent policy assures the public that the government supports access to life-saving drugs, fostering healthy lives. It also encourages the industry to invest more resources in research and development. A decline in the number of breakthroughs in the field has been linked to insufficient support. Having stable policies enhances access to these drugs, prevents unnecessary health complications, and limits economic burdens arising from cardiovascular diseases.

Reimbursement policies and programs have also led to the development and availability of cheaper alternatives to costly cardiovascular drugs. The rise of generic versions of the same drug has quelled profit-motivated demands and increased affordability. Such competition has made life-saving drugs more accessible for those living in low-income areas.

The benefits of reimbursement programs have also led to increased awareness of cardiovascular diseases. Through these programs, patients and healthcare providers have access to information on treatment as well as prevention methods. It promotes adherence to a healthier lifestyle, which could prevent the onset of future cardiovascular complications. As a result, insurance companies, the government, and pharmaceutical companies have all joined hands to increase awareness programs, benefiting the public in the process.

The inclusion of cardiovascular drugs in a healthcare plan or insurance boosts the well-being and prosperity of individuals and the community. The economic benefits arising from access to healthcare play a vital role in the progress of a society. Favorable reimbursement policies and programs increase productivity, reduce absenteeism, and enhance health literacy. This leads to better decisions and less overall waste of resources to overcome health crises.

Favorable reimbursement policies and programs for cardiovascular drugs bring worth beyond its cost, promoting access to crucial treatments, affordable alternatives, increased awareness and health literacy, and economic prosperity to a community. It is the collective responsibility of the government, healthcare providers, patients, and the pharmaceutical industry to ensure the efficacy of such policies to improve public health and healthcare infrastructure. An investment in cardiovascular disease prevention and treatment through the implementation of favorable reimbursement policies and programs will produce bountiful returns as the health sector advances.

Frequently Asked Questions
  1. How big is the Cardiovascular Drugs Market?
    Ans. The Global Cardiovascular Drugs Market size was estimated at USD 82.65 billion in 2023 and expected to reach USD 90.13 billion in 2024.
  2. What is the Cardiovascular Drugs Market growth?
    Ans. The Global Cardiovascular Drugs Market to grow USD 152.61 billion by 2030, at a CAGR of 9.15%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.